Nasus Pharma Ltd. Stock Price

NYSEAM:NSRX Community·US$67.9m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

NSRX Share Price Performance

US$0

-8.25 (-100.00%)

US$0

-8.25 (-100.00%)

US$0

Fri, 26 Dec 25

Share Pricen/a

NSRX Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Medium-low risk with weak fundamentals.

6 Risks

0 Rewards

View Full Analysis

Nasus Pharma Ltd. Key Details

Last Reported Earnings

Dec 31, 2024

Next Reporting Earnings

n/a

: -0.17
: 0%
: 0%
: -56.1%

View Full Analysis

About NSRX

Founded: 2019
Employees: 2
CEO: Dan Teleman
WebsiteView website: www.nasuspharma.com

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.